Compounding allows pharmacists to create customized doses that arent available through commercial products
The SURMOUNT-1 trial (N=2,539), published in the New England Journal of Medicine in 2022 (DOI: 10.1056/NEJMoa2206038), evaluated tirzepatide at 5mg, 10mg, and 15mg weekly doses versus placebo in adults with obesity or overweight
Enjoy your medication at unparalleled discounts while reaping rewards for every step you take with us
In short, if you were using a TRICARE weight loss covered medication and fall under the TFL category, youll likely need to pay out of pocket after August 31, 2025
Made for real life on GLP-1
Measuring biomarkers like fasting insulin, C-peptide, and inflammatory markers (hsCRP) can provide context for whether your metabolic profile aligns with conditions where prescription GLP-1 therapy has the strongest clinical evidence